The tirzepatide weight loss results show how the dual GIP/GLP-1 mechanism produces additional weight loss beyond what semaglutide achieves alone
Intranasal delivery is the most evidence-supported non-injectable route for CNS-targeting peptides because it bypasses the blood-brain barrier via the olfactory-trigeminal pathway, not because peptides passively diffuse through nasal mucosa into systemic circulation
Randomized trials (direct AD studies) Liraglutide (ELAD Phase 2b): In people with mild AD, 12 months of liraglutide slowed brain atrophy (MRI) and was associated with an ~18% slower cognitive decline versus placeboencouraging but still preliminary and not yet a practice-changing Phase 3 outcome
Semaglutide is approved by the Food and Drug Administration (FDA) for two primary purposes: Managing Type 2 Diabetes: Type 2 diabetes occurs when your body doesnt use insulin effectively or doesnt produce enough of it
who shared the 1985 Nobel Prize in Physiology or Medicine for their work furthering the understanding of cholesterol metabolism discovered SREBPs, a family of proteins that regulate cholesterol and fatty acid synthesis
Evidence supports its use in that population
